EPISODE · Apr 17, 2024 · 12 MIN
Wegovy for Cardiovascular Risk Reduction - Part 2
from Weight and Healthcare · host Ragen Chastain
In part one we looked at the staggering conflicts of interest and issues with the efficacy in the Semaglutide 2.4 (Wegovy) cardiovascular trial (Semaglutide and Cardiovascular Outcomes in Ob*sity* without Diabetes DOI: 10.1056/NEJMoa2307563) especially as compared to the deeply misleading claims in Novo Nordisk’s “company announcement” publicity stunt prior to publication.Today we’re going to dig deeper into the data, what there is of it, anyway. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe
NOW PLAYING
Wegovy for Cardiovascular Risk Reduction - Part 2
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m